<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1122490742015118&amp;ev=PageView&amp;noscript=1">

Assessing TRIV202 To Reverse Subvalular Aortic Stenosis (SAS) In Dogs


TriviumVet is supplying TRIV202 to the Morris Animal Foundation research into subvalvular aortic stenosis (SAS), the most common congenital heart defect in dogs. The purpose of this study is to evaluate whether three-times weekly dosing with oral rapamycin (TRIV202) can reverse the heart muscle changes associated with SAS in dogs. As the current treatment options are limited in this disease, this has the potential to provide further treatment options to improve quantity and quality of life for dogs affected by this disease. 

RAPASAS Study Graphic

Register For Trial Today!

We invite you to be a part of something truly meaningful - a pharmaceutical trial that has the potential to improve the lives of pets worldwide. By registering your beloved furry companion for our trial, you are taking a step towards a brighter and healthier future for them and countless other animals.

Fill In Your Details Here 👇

Free Downloads

RapaSAS Study Flyer Smaller Mockup

RAPASAS Study Flyer